Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

This study has been completed.
Sponsor:
Collaborator:
Vietnam National University
Information provided by (Responsible Party):
Vuong Thi Ngoc Lan, Ho Chi Minh City University of Medicine and Pharmacy
ClinicalTrials.gov Identifier:
NCT01493440
First received: December 14, 2011
Last updated: December 16, 2011
Last verified: December 2011
  Purpose

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).


Condition Intervention
Repeated Implantation Failure
Drug: atosiban

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Resource links provided by NLM:


Further study details as provided by An Sinh Hospital:

Primary Outcome Measures:
  • Clinical pregnancy [ Time Frame: 5 weeks after intervention ] [ Designated as safety issue: No ]

Enrollment: 71
Study Start Date: March 2011
Study Completion Date: September 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Atosiban Drug: atosiban
Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Other Name: Tractocile

Detailed Description:

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • had repeated implantation failure
  • have at least 1 good quality embryo for transfer

Exclusion Criteria:

  • uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01493440

Locations
Vietnam
IVFAS, An Sinh Hospital
Ho Chi Minh City, Ho Chi Minh, Vietnam, 8
Sponsors and Collaborators
An Sinh Hospital
Vietnam National University
Investigators
Principal Investigator: Lan TN Vuong, MD University of Medicine and Pharmacy of Ho Chi Minh City
  More Information

No publications provided

Responsible Party: Vuong Thi Ngoc Lan, Lecturer and Researcher, Department of Obstetrics and Gynecology, Ho Chi Minh City University of Medicine and Pharmacy
ClinicalTrials.gov Identifier: NCT01493440     History of Changes
Other Study ID Numbers: IVFAS1103
Study First Received: December 14, 2011
Last Updated: December 16, 2011
Health Authority: Vietnam: Ministry of Health

Keywords provided by An Sinh Hospital:
atosiban
clinical pregnancy
implantation rate
uterine contractility
IVF-ET

Additional relevant MeSH terms:
Atosiban
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Tocolytic Agents
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 18, 2014